Clin2
NCT06008197Likely a fitRecruiting

A study of finerenone for hospitalized heart failure patients

Heart FailureAcute Heart Failure

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
5,200 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are currently in the hospital for heart failure, or have been discharged within the last 30 days.
  • You have had symptoms and signs of heart failure during this hospital stay.
  • An imaging test shows your heart's pumping strength is 40% or higher (mildly reduced or preserved).
  • You have elevated levels of a heart stress marker in your blood (NTproBNP or BNP).
  • You are not currently taking or planning to take a specific type of heart pill called a mineralocorticoid receptor antagonist (MRA).
  • Your kidney function is above a certain level and your potassium level is not too high.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07583173Not yet recruiting· Phase 4
Finerenone for heart failure with preserved ejection fraction

This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.

Beijing
NCT07397650Recruiting· Phase 4
Early finerenone for heart failure in hospital

This trial tests if starting finerenone early helps patients hospitalized with heart failure who have symptoms like shortness of breath or swelling. It aims to see if the drug is safe and effective when given soon after admission.

Handa, Aichi-ken
NCT06033950Recruiting· Phase 3
A study of finerenone for heart failure patients who can't take standard MRA drugs

This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.

Fairhope, Alabama
NCT07442448Enrolling by invitation· Phase 4
Study of Finerenone for heart and kidney health in diabetes

This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.

Taipei
NCT07270367Not yet recruiting· Phase 3
Finerenone study for heart thickening

This trial tests if a medication called finerenone can improve heart structure and function in people whose heart walls are thickened. It may help people with early heart failure or related conditions like diabetes or kidney disease.

Cambridge, Ontario
NCT06024746Recruiting· Phase 3
Finerenone plus SGLT2i for hospitalized heart failure

This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.

Fairhope, Alabama

Hear when a new Heart failure trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.